Category: Press Release - Page 34 - Psychedelic Alpha

Read more about the article Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Post published:January 5, 2023
Post category:Press Release

Read more about the article Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

Post published:January 5, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

Post published:January 3, 2023
Post category:Press Release

Read more about the article Clearmind Medicine Announces Shareholders Meeting Results

Clearmind Medicine Announces Shareholders Meeting Results

Post published:December 29, 2022
Post category:Press Release

Read more about the article Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

Post published:December 28, 2022
Post category:Press Release

Read more about the article Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property

Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property

Post published:December 24, 2022
Post category:Press Release

Read more about the article Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Post published:December 24, 2022
Post category:Press Release

Read more about the article Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute

Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute

Post published:December 21, 2022
Post category:Press Release

Read more about the article Numinus to Participate in the KCSA Mental Health Virtual Investor Conference on December 15, 2022

Numinus to Participate in the KCSA Mental Health Virtual Investor Conference on December 15, 2022

Post published:December 21, 2022
Post category:Press Release

Read more about the article Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care

Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care

Post published:December 21, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.